1. Home
  2. CL vs REGN Comparison

CL vs REGN Comparison

Compare CL & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Colgate-Palmolive Company

CL

Colgate-Palmolive Company

N/A

Current Price

$87.70

Market Cap

73.2B

ML Signal

N/A

Logo Regeneron Pharmaceuticals Inc.

REGN

Regeneron Pharmaceuticals Inc.

N/A

Current Price

$801.56

Market Cap

68.8B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CL
REGN
Founded
1806
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Package Goods/Cosmetics
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
73.2B
68.8B
IPO Year
2008
1995

Fundamental Metrics

Financial Performance
Metric
CL
REGN
Price
$87.70
$801.56
Analyst Decision
Buy
Buy
Analyst Count
17
25
Target Price
$94.19
$830.16
AVG Volume (30 Days)
3.6M
541.9K
Earning Date
05-01-2026
04-29-2026
Dividend Yield
2.51%
0.55%
EPS Growth
N/A
8.19
EPS
1.67
18.95
Revenue
$15,454,000,000.00
$5,872,227,000.00
Revenue This Year
$7.49
$12.45
Revenue Next Year
$3.28
$10.13
P/E Ratio
$52.94
$42.76
Revenue Growth
1.70
20.82
52 Week Low
$74.55
$541.00
52 Week High
$99.33
$859.34

Technical Indicators

Market Signals
Indicator
CL
REGN
Relative Strength Index (RSI) 36.98 51.96
Support Level $84.19 $732.04
Resistance Level $89.34 $818.06
Average True Range (ATR) 1.33 18.05
MACD -0.33 -6.43
Stochastic Oscillator 3.48 28.56

Price Performance

Historical Comparison
CL
REGN

About CL Colgate-Palmolive Company

Since its founding in 1806, Colgate-Palmolive has grown into a leading player in the household and personal care industry. In addition to its namesake oral care line (which accounts for more than 40% of its total sales), the firm manufactures shampoos, shower gels, deodorants, and home care products sold in over 200 countries. International sales account for about 70% of its total business, including nearly half from emerging regions. It also owns specialty pet food maker Hill's (almost one-fourth of sales), which sells the majority of its products through veterinarians and specialty pet retailers.

About REGN Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.

Share on Social Networks: